GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Research & Development

AbCellera Biologics (STU:8QQ) Research & Development : €149.92 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. AbCellera Biologics's Research & Development for the three months ended in Mar. 2024 was €36.14 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was €149.92 Mil.


AbCellera Biologics Research & Development Historical Data

The historical data trend for AbCellera Biologics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Research & Development Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 9.10 24.16 54.93 101.84 161.08

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 49.17 33.67 35.53 44.59 36.14

AbCellera Biologics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €149.92 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics  (STU:8QQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


AbCellera Biologics Research & Development Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (STU:8QQ) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines